Khissya Beatryz Alves de Lima

Khissya Beatryz Alves de Lima

Auto-generated profile, based on publicly available information

Khissya Beatryz Alves de Lima

Department of Medicine, Federal University of Goiás, Goiânia, GO 74605-050, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2025 in Cells
Verified
Journal Article
Open access
PDF file
Antonio da Silva Menezes JuniorAntonio da Silva Menezes Junior
Antonio da Silva Menezes Junior
Henrique Lima de OliveiraHenrique Lima de Oliveira
Henrique Lima de Oliveira
KLKhissya Beatryz Alves de Lima
Khissya Beatryz Alves de Lima
SBSilvia Marçal Botelho
Silvia Marçal Botelho
MAMelissa Avelino
Melissa Avelino
Background: Hypertrophic cardiomyopathy (HCM) is increasingly recognized as a disorder shaped not only by sarcomeric mutations but also by complex immunogenetic and metabolic interactions. Emerging transcriptomic and single-cell analyses implicate immune dysregulation, RNA methylation, and necroptosis as critical modulators of myocardial remodeling. Objectives: This scoping review synthesizes bioinformatic, transcriptomic, and experimental data to delineate the immunogenetic architecture of HCM and identify candidate molecular targets for immune–metabolic modulation. Methods: Following Joanna Briggs Institute and PRISMA-ScR guidelines, we systematically searched PubMed, Embase, Web of Science, and GEO through September 2025 for studies evaluating immune infiltration, RNA regulation, and necroptosis in human HCM. Data were narratively synthesized across histologic, clinical, and multi-omics domains. Results: Among 8191 screened records, 25 studies met the inclusion criteria. Key immune–epigenetic regulators included the lncRNA–mRNA pair MIR210HG–BPIFC, m6A readers IGFBP3 and YTHDC1, and necroptosis gene JAK2. The HCM myocardium exhibited the depletion of reparative M2 macrophages and Tregs; enrichment of cytotoxic CD8+ T cells; and activation of the TNFα–NFκB, IL-6–JAK–STAT3, and PI3K–Akt pathways. Machine learning biomarkers (RASD1, FCN3, and PIK3R1) exhibited diagnostic accuracy (AUC > 0.85). Drug target predictions identified ruxolitinib and celecoxib as potential immunometabolic modulators (agents predicted to modulate both immune and metabolic pathways based on gene expression signatures). Conclusions: These findings support a hypothesis that HCM may involve immunogenetic mechanisms, rather than being exclusively sarcomeric in nature, although this remains to be validated. The integration of molecular and imaging biomarkers may enable precision immunotherapy, redefining HCM from a structural cardiomyopathy to a biologically stratified condition.

9 June 2026 in Frontiers in Bioscience-Scholar
Verified
Journal Article
Open access
PDF file
Antonio da Silva Menezes JuniorAntonio da Silva Menezes Junior
Antonio da Silva Menezes Junior
Henrique Lima de OliveiraHenrique Lima de Oliveira
Henrique Lima de Oliveira
KLKhissya Beatryz Alves de Lima
Khissya Beatryz Alves de Lima
Background: Hypertrophic cardiomyopathy (HCM) is genetically heterogeneous and characterized by left ventricular hypertrophy, myocardial fibrosis, and diverse clinical manifestations. Although circulating microRNAs (miRNAs) are promising biomarkers of pathological cardiac remodeling, the correlation of these miRNAs with specific clinical characteristics of HCM remains unclear. Therefore, we systematically reviewed and quantified the correlation between circulating miRNAs and structural and functional cardiac parameters in HCM. Methods: This systematic review and meta-analysis of observational studies evaluated the association between circulating miRNA expression levels and Echocardiography, magnetic resonance imaging, and histological parameters for HCM. We comprehensively searched the PubMed, Embase, Scopus, and Web of Science databases, and extracted and transformed correlation coefficients into Fisher’s Z-scores. The study was registered with PROSPERO under registration number CRD420251058653. Meta-analyses were conducted using random-effects models, and heterogeneity was assessed using the I2 statistic. Sensitivity analyses, meta-regression, and publication bias were also assessed. Results: A total of 11 studies comprising 633 patients were included. Pooled analysis showed moderate-to-strong positive correlations between miRNAs (miR-21, miR-29a, miR-199a-5p, and miR-27a) and myocardial fibrosis, wall thickness, and left ventricular mass (r = 0.53; 95% confidence interval 0.40–0.64; I2 = 60.1%). Sensitivity and meta-regression analyses confirmed the robustness of the results, with no significant publication bias. The risk-of-bias assessment (Quality Assessment of Diagnostic Accuracy Studies 2) revealed moderate concerns, primarily related to patient selection and index-test blinding. Conclusion: Circulating miRNAs were significantly correlated with structural and functional cardiac changes in HCM, supporting the potential role of these miRNAs as noninvasive biomarkers. However, further high-quality studies are needed to validate their clinical applicability.